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We have previously shown that a hydrophobic alkylating compound, 1,5-iodonaphthyl-azide (INA) can
efficiently inactivate the virulent strain of Venezuelan equine encephalitis virus (VEEV), V3000 in vitro. In
this study, we have evaluated the safety of INA-inactivated V3000 and V3526 and the protective efficacy
of INA-inactivated V3000. INA-inactivated V3000 and V3526 did not cause disease in suckling mice. RNA
isolated from the INA-inactivated V3000 and V3526 was also not infectious. Immunization of adult mice
with INA-inactivated V3000 induced an anti-VEEV antibody response and protected mice from virulent
VEEV challenge. The protective efficacy of INA-inactivated V3000 increased with the use of adjuvants.
Results suggest that inactivation of enveloped viruses by INAmay occur by two independentmechanisms
and the INA-inactivated VEEV elicit a protective antibody response in mice.
© 2010 Elsevier Ltd. All rights reserved.
1. Introduction
Venezuelan equine encephalitis virus (VEEV) is amember of the
genus Alphavirus in the family Togaviridae. VEEV causes periodic
outbreaks of disease in Latin and South America and is an emerging
pathogen [1]. VEEV is highly infectious in aerosol form in mice and
non human primates [2,3] and was characterized as a bioweapon
[4]. VEEVhas beendesignated aCategoryBpriority pathogenby the
National Institute of Allergy and Infectious Disease. VEEV is trans-
mitted by mosquito in nature [5–7] and causes disease of varying
severity in horses and humans [8,9].
There is no licensed vaccine available for prophylaxis against
VEEV. A live attenuated TC-83 vaccine for VEEV is currently used
under investigational new drug (IND) status and is administered
to laboratory personnel at risk. However, TC-83 has residual viru-
lence in suckling mice [10] and infection of pregnant mice with
TC-83 results in stillbirth and decreased litter size of newborns
[11]. TC-83 vaccine is also detrimental for the human fetus [12].
Further limitations of TC-83 vaccine in humans include short-lived
immunity and approximately 20% non-responders [13,14]. Forma-
lin inactivated TC-83, known as C-84, is used as a booster following
immunization with live, attenuated TC-83 vaccine. This vaccine is
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also used under IND status, has short-lived immunity and requires
frequent boosts [14,15]. An attenuated strain, V3526, which has a
deletion mutation at the furin cleavage site between the E2 and E3
glycoproteins of the Trinidad donkey strain of VEEV [16] has been
extensively evaluated as a VEEV vaccine candidate [17–20]. V3526
has excellent immunogenic activity, but also causes febrile illness
and low level neurotropism in non human primates [17,18,21–23].
In phase I clinical trial, V3526 induced a robust immune response;
however, a high frequency of fever and a flu-like syndrome were
reported which led to the cessation of the development of V3526
as a live attenuated vaccine [24,25].The residual virulence associ-
atedwith the vaccine candidates has again focused the attention on
the inactivated vaccine preparation. We have previously demon-
strated that 1,5 iodonaphthyl azide (INA) completely inactivated
the virulent strain of VEEV, V3000 in vitro [26]. INA is a hydrophobic
photoactive aryl azide that sequesters in the hydrophobic domain
of the biological membranes. Irradiation with ultra-violet light
results in covalent binding of INA to lipids and proteins embedded
in the membrane bilayer [27,28]. This results in the inactivation
of the membrane proteins without affecting the ectodomain of
these proteins that is protruding outside the membrane bilayer
[29,30]. This mechanism of action of INA was exploited to inac-
tivate other viruses such as HIV, SIV, Ebola and influenza virus
[31–33].
In this study, we have evaluated the safety and protective
efficacy of INA inactivated-V3000 in mice. We also demonstrate
in vitro that INA can efficiently inactivate the live attenuated
vaccine strain V3526 of VEEV. These results are important as these
establish a proof of concept that INA-inactivated VEEV is safe
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and immunogenic and can be further explored for developing an
inactivated VEEV vaccine.
2. Materials and methods
2.1. Virus and animals
Virus: Molecularly cloned virulent strain of VEEV, V3000 [8] and
an attenuated strain, V3526 [34] were used in the present study.
Animals: Swiss CD-1 mice, 5–6 weeks old and 1 day old CD-1
pups and dams were purchased from Charles River Laboratories,
Wilmington, MA. Mice were housed in microisolator cages and
were provided food and water ad libitum with a 12h light/dark
cycle. All experiments with V3000 virus strain were carried out in
a bio-safety level 3 (BSL-3) facility at Uniformed Services Univer-
sity of TheHealth Sciences (USUHS), Bethesda,MD. All experiments
were conducted in accordance with the Guide for the Care and Use
of Laboratory Animals (Committee on Care And Use of Laboratory
Animals of The Institute of Laboratory Animal Resources, National
Research Council, NIH Publication No. 86–23, revised 1996).
2.2. Inactivation of VEEV with 1,5 iodonaphthylazide (INA)
INA was kindly provided by Drs. Robert Blumenthal and Yossef
Raviv, National Cancer Research Institute, NIH Frederick,MDunder
a material transfer agreement. V3526 and V3000 were inactivated
with INA as described before [26]. Briefly, purified viral stocks with
known titers were suspended in 1×Dulbecco’s Phosphate Buffered
Saline (DPBS) (GIBCO, Invitrogen Corporation, Carlsbad, CA) at a
protein concentration of 0.5mg/ml. The preparations were then
passed through30 gaugeneedle syringe to disperse any viral aggre-
gates in the suspension. Under reduced light conditions, 2–2.5l
aliquots of 20mM INA were added to the virus suspension (final
concentration100M)along thewall of anultra clear 1.5mlmicro-
centrifuge tube (GeneMate, Catalog No. C-3269-1, ISC Bioexpress,
Kaysville, UT) followedby immediate vortexing after each addition.
Samples were incubated for 20min in the dark at room tempera-
ture and then centrifuged at 1000 rpm for 1min to remove any
precipitated INA. The supernatant was transferred to a new tube
and 20l of 1M glutathione was added at a final concentration
of 20M to quench any unbound INA present in the solution. The
virus suspensionwas vortexed and irradiated using 100Wmercury
UV lamp as described previously [26]. Briefly, the virus suspension
was irradiated twice for 90 s and once for 120 s followed by vor-
texing each time. Thereafter full light conditions were used and
samples were stored at −80 ◦C. Virus titers were back calculated
and dilutions were made accordingly for testing the infectivity
of INA-inactivated V3526 and INA-inactivated V3000. Therefore,
all the doses of INA-inactivated V3526 and INA-inactivated V3000
are plaque forming unit (pfu) equivalent of corresponding virulent
VEEV strain.
2.3. Determination of cytopathic effect (CPE assay)
Vero cells were plated in 24-well tissue culture plates and
infected with V3526 or INA-inactivated V3526 at a multiplicity of
infection (MOI) of 1.0 and incubated at 37 ◦C and 5% CO2 incubator.
Virus was removed after 1h incubation and freshmedia was added
to the cells after washing once with 1× DPBS. Cells were observed
for cytopathic effect such as rounding and sloughing off from the
surface.At72hpost-infection (p.i.) cell supernatantswerecollected
from the wells and cells were stained with 0.1% crystal violet (CV)
in 2% neutral buffered formalin (NBF) solution, for 10min at room
temperature (RT).
2.4. Virus titration by plaque assay
Virus titers in the brain of suckling mice were determined
by standard plaque assay. Twenty percent (weight/volume) brain
samples were prepared by homogenizing brain tissue in 1× PBS
supplementedwith 0.1% bovine serum. Nearly confluentmonolay-
ers of Vero cells in 60mmculture disheswere incubatedwith serial
dilutions of the samples for 1h at 37 ◦C and 5% CO2 incubator and
then were rinsed once with 1× DPBS. Agarose overlay (1% agarose,
1×MEM,6%newborn calf serumand0.5%penicillin–streptomycin)
was added to the cells and plates were incubated at 37 ◦C and 5%
CO2 incubator. Plaques were visualized and counted at 96h p.i by
staining the cells with 0.1% CV in 2% NBF solution for 10min at RT.
2.5. Reverse transcription-PCR (RT-PCR)
Total RNAwas isolated from the brains of intracranial (i.c.) inoc-
ulated V3526 (day 4 p.i.) and INA-inactivated V3526 (day 13 p.i.)
mice using the TriZol reagent (Invitrogen Inc., Carlsbad, CA) accord-
ing tomanufacturer’sprotocol. Similarly totalRNAwasalso isolated
from Vero cells infected with V3526 and INA-inactivated V3526
(MOI =10) at 48h p.i.
cDNA was made from the total RNA using the SuperScript III
First-Strand Synthesis kit (Invitrogen Inc., Carlsbad, CA) according
to manufacturer’s protocol. Briefly, 1g of total RNA was mixed
with 2.0l of enzyme mix, 10l of 2× buffer and nuclease free
water was added to a final reaction volume of 20l. The reaction
mixture was incubated at RT for 10min followed by incubation at
50 ◦C for 30min and 85 ◦C for 5min. Samples were kept on ice for
2min and 1l of RNaseH was added followed by an incubation at
37 ◦C for 20min.
V3526 specific PCR for the nonstructural protein 4 (nsP4)
gene (virus RNA dependent RNA polymerase) was performed
to evaluate the virus infection in vitro. GAPDH served as a
house keeping gene. Primer sequences used for nsP4 gene
were: Forward- 5′GCTAACAGAAGCAGATACCAG3′; Reverse-
5′GCAGCCGAATCCAATACGGGC3′. Primer sequences used for
GAPDHgenewere: Forward- 5′CCATCACCATCTTCCAGGAGCGAG3′;
Reverse- 5′CACAGTCTTCTGGGTGGCAGTGAT3′. PCR supermix
(Invitrogen Inc., Carlsbad, CA) was used to perform the PCR. Reac-
tionmixture consisted of 45l of PCR supermix, 1l (30ng) of each
primer and 2l of cDNA. The following PCR cycle was used: initial
denaturation at 95 ◦C for 3min, followed by 25 cycles of denatura-
tion at 95 ◦C for 30 s, annealing at 62 ◦C for 45 s, and extension at
72 ◦C for 30 s. A final extension was done at 72 ◦C/5min.
2.6. Evaluation of virus genome for infectivity
The RNA genome was isolated from 500l of INA-inactivated
V3000 and similarly diluted 500l of virulent V3000 using Pure-
Link viral RNA/DNA mini kit (Invitrogen, Carlsbad, CA) as per
manufacturer’s protocol. RNA was eluted into a final volume of
20l. RNA from two samples was pooled together and quantitated
using a Beckman 640 spectrophotometer (Beckman instruments
Inc., Columbia, MD, USA). RNA, was transfected into cells using the
siPORT Amine transfection reagent (Applied Biosystems/Ambion,
Austin, TX) as per manufacturer’s protocol. Briefly, the RNA
(100g) was mixed with the transfection reagent and incubated
at room temperature for 20min. Following the incubation, BHK
cells suspended in fresh 1× MEM medium (without antibiotics)
were added to the RNA transfection mixture and plated in 8-
well chamber slides. After 12h, the transfection reagent mix was
removed and replaced with fresh 1× MEM media (with antibi-
otics). Cells were incubated for 48h and then fixed with chilled
1:1::acetone:methanol solution for 10min. Slideswere then stored
at −20 ◦C until stained for VEEV antigen as described below.
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Fig. 1. Inactivation of V3000 genomic RNAby INA. BKH cellswere transfectedwithV3000 genomic RNA isolated fromeither virulent V3000 or INA-inactivatedV3000. (a) Cells
infected with virulent V3000 virus (positive control for infection); (b) Cells treated with saline; (c–e) Cells transfected with RNA isolated from three different INA-inactivated
V3000 samples; and (f) Cells transfected with RNA isolated from virulent V3000. Transfection of cells with virulent V3000 RNA resulted in active VEEV replication indicated
by positive staining for VEEV antigen (green). This replication was comparable to the infection of cells with virulent virus (a). Cells transfected with INA-inactivated VEEV
RNA were negative for VEEV replication similar to saline control. Nuclei were stained blue using 4′ ,6-diamidino-2-phenylindole (DAPI). (For interpretation of the references
to colour in this figure legend, the reader is referred to the web version of this article.)
2.7. Immunofluorescence for VEEV antigen
V3000 (Fig. 1) and V3526 (Fig. 4) antigen specific immunofluo-
rescencewas done as described previously [26]. Briefly, slideswere
rinsed thrice with 1× PBS for 5min each and nonspecific binding
was blocked using 1% BSA for 1h at room temperature. Excess BSA
was removed and slides were incubated with 1:1000 diluted poly-
clonal rabbit anti-VEEV antibody (kindly provided by Dr. Franziska
B. Grieder, USUHS, Bethesda, MD) for 1h at 37 ◦C. Slides were then
rinsed thrice with 1× PBS for 5min each and incubated with FITC-
conjugated goat anti-rabbit IgG (1:1000) for 30min at 37 ◦C. This
antibody recognizes both V3526 and V3000 strains of VEEV. Slides
were washed thrice with 1× PBS for 5min each, mounted with
vectashield mounting medium containing DAPI (Vector laborato-
ries, Inc., Burlingame, CA), and were observed under fluorescence
microscope.
2.8. Residual virulence evaluation in suckling mice
For the entire in vivo study, stock virus suspension was diluted
to desired working suspension in 1× DPBS.
Suckling mice study with V3000 and V3526: Five day old mice
were infected intraperitoneally (i.p.) with 10,000pfu of virulent
V3000 or INA-inactivated V3000 (n=9 or n=10, respectively) in a
final volume of 20l. Nine day old mice were infected intracra-
nially (i.c.) with 10,000pfu of INA-inactivated V3000 (n=10) or
virulent V3000 (n=9) in a final volume of 20l. Three days old
mice were infected i.c. with 10,000pfu of V3526 (n=8) or INA-
inactivated V3526 (n=10) in a final volume of 20l. Control mice
(n=2) were similarly injected with 1× phosphate buffered saline
(PBS). Animals were observed for a period of 2 weeks for the devel-
opment of any clinical signs of disease and infection. Brain tissues
were collected from all mice at the end of two weeks observation
period and were stored at −80 ◦C.
2.9. Immunization and protection study
Three separate immunization studies were undertaken. Five to
six weeks oldmale CD-1mice were injected intraperitoneally with
the INA-inactivated V3000 on day zero. At 7th day post last vacci-
nation,micewere challengedwith virulent V3000 virus.Micewere
anesthetized using inhalation anesthesia, isofluorane using a “drop
jarmethod” asdescribedbefore [35] and1000pfuof virulentV3000
were inoculated in the rear footpad of each mouse.
First study: n=6. Booster doses were given at day 7 post
first immunization (pfi) and day 14pfi. Immunization consisted
of 10,000 INA-inactivated pfu of V3000. Six age-matched non-
vaccinated mice were included as control. On the day 21pfi,
blood was collected by tail vein nick and serum was iso-
lated. Mice were then challenged with virulent V3000 strain of
VEEV.
Second study: n=10 per group. Booster doses were given at days
7, 14 and 21pfi. First two booster doses consisted of 10,000pfu
of INA-inactivated V3000 and the third booster dose consisted of
50,000pfu of INA-inactivated V3000. On the day 28pfi blood was
collected by tail vein nick and serum was isolated. On day 29pfi
micewere challengedwith virulent V3000. Three individual groups
were examined: (1) INA-inactivated V3000 alone.Mice were immu-
nizedwith the INA-inactivatedV3000 formulation alone for all four
immunizations. (2) INA-inactivated V3000 with Alhydrogel as adju-
vant. Alhydrogel® (Brenntag Biosector, Fredeikssund, Denmark)
was first diluted to a working suspension containing 2mg/ml of
aluminum in 1× DPBS. INA-inactivated V3000 was mixed with
dilutedAlhydrogel in equal volumes. Thismixturewas then contin-
uously vortexed for 2h at room temperature. Animals were given
four immunizations of this INA-inactivated V3000-Alhydrogel for-
mulation. (3) INA-inactivated VEEV with Complete Freund’s adjuvant
(CFA). INA-inactivated V3000 was mixed with the equal volume of
CFA just prior to immunization. Only the first immunization was
given with the INA-inactivated V3000-CFA formulation and the
subsequent three immunizations contained only INA-inactivated
V3000. Ten age-matched non-vaccinated mice were included as
controls.
Third-study: Nineteenmice were immunized with 50,000pfu at
day zero followed by two booster immunizations with 50,000pfu
each at day 7 andday14pfi. Five age-matchednon-vaccinatedmice
were included as control. On day 21pfi, mice were challengedwith
virulent V3000 strain of VEEV.
956 A. Sharma et al. / Vaccine 29 (2011) 953–959
In all the three studies mice were monitored for the clinical
symptoms of disease andmortality for 14 days after challengewith
virulent virus.
2.10. Enzyme-linked immunosorbent assay for detecting
anti-VEEV antibody in serum
Blood was incubated on ice for 30min and then centrifuged
at high speed for 30min. The aqueous layer of serum was then
collected and immediately stored at −80 ◦C. For enzyme-linked
immunosorbent assay (ELISA), 96 well Immulon 4HBX ultra-high
binding polystyrene microtiter plates (Thermo Electron Corp., Mil-
ford, MA) were coated with 5g of virulent V3000 strain of VEEV
perwell in 50l volumeat 4 ◦Covernight. The virus suspensionwas
then removed andplateswere blockedwith 1%Bovine SerumAlbu-
min (BSA) (50l/well) at 4 ◦C overnight. Blocking agent was then
removed and 50l serially diluted serum (1:50, 1:250, 1:625 and
1:1250) was added to wells in triplicates. Plates were then incu-
bated for 4h at 37 ◦C followed by two washes, first with 0.05%
Tween 20 in 1× PBS and then with distilled water. An aliquot
(50l) of alkaline phosphatase conjugated goat anti-mouse IgG
(secondary antibody) (1:1000) was added to each well and incu-
bated at 37 ◦C for 1h. Plates were then washed twice first with
0.05% Tween 20 in 1× PBS and then with distilled water. Phos-
phatase substrate (Sigma–Aldrich, St. Louis, MO) was then added
(50l/well of 5mg/ml) and colorwas allowed todevelop for 10min
at 37 ◦C. Plates were read at 405nmwavelength using ELISA reader
(Bio-Rad Laboratories, Inc., Hercules, CA 94547).
3. Results and discussion
In our previous study [26] we demonstrated that V3000 virus,
rescued from a cDNA of VEEV [8], can be completely inactivated
with INA in vitro. In this study we tested the safety and protec-
tive efficacy of INA-inactivated V3000 in mice. To test the residual
virulence that may be associated with the INA-inactivated VEEV,
suckling mice were inoculated with INA-inactivated V3000 and
were observed for disease morbidity. Suckling mice are immuno-
logically immature and fail to or induce inadequate antibody
response to infection [36]. The immature neurons are also more
susceptible to virus induced apoptosis [37]. Therefore, these mice
should be sensitive to any residual virulence that may be associ-
ated with inactivated preparations of virus. None of the suckling
mice infected with INA-inactivated V3000 (i.p. or i.c.) showed
any clinical sign of disease and survived the two week observa-
tional period (Table 1). Mice that received V3000 succumbed to
the virus infection within 48h p.i. The positive sense RNA genome
of alphaviruses is infectious and when transfected into sensitive
cell lines results in the generation of live virus particles [38,39].
Table 1
Safety evaluation in suckling mice.
Group(s) Percent survival Mice died/total mice
V3000 (i.p.) 0 10/10
V3000+ INA+ IRRAD (i.p.) 100 0/9
V3000 (i.c.) 0 9/9
V3000+ INA+ IRRAD (i.c.) 100 0/10
V3526 (i.c.) 0 8/8
V3526+ INA+ IRRAD (i.c.) 10 0/10
Suckling mice were infected with virulent and INA-inactivated viruses as described
in Section 2. All the animals that received INA-inactivated virus (either V3000 or
V3526) survived and developed normally. As expected, animals that received V3000
by either route (i.c. or i.p.) succumbed to the infectionwith in 48hp.i. All the animals
that received virulent V3526 either succumbed to the infection or were humanely
euthanized due to the severe disease morbidity at 96h p.i.
BHK cells were transfectedwith RNA isolated from INA-inactivated
V3000. Immunofluorescence staining forVEEVantigenshowedthat
RNA isolated from INA-inactivated V3000was non-infectious. Pos-
itive VEEV staining was observed in the cells that were transfected
with RNA isolated from virulent V3000. The staining was similar to
that of V3000 virus infection. The cells that were transfected with
the RNA from INA-inactivated V3000 did not show any staining for
VEEV antigen and were similar to that of negative controls (Fig. 1).
These results indicate that INA may have another mechanism of
virus inactivation independent of protein binding. This is a novel
finding as INA was only known to inactivate virus by binding to
the viral proteins [31,40]. Since VEEV RNA is infectious, its inacti-
vation by INA may further reduce the residual virulence that may
be associated with infectious RNA of otherwise inactivated VEEV.
Incompletely inactivated VEEV vaccine was believed to be respon-
sible for some of the outbreaks of VEEV [1]. Thus inactivation of
VEEV RNA by INA may provide another level of protection against
incomplete inactivation seenwith other inactivationmethods. Fur-
ther studies are in progress to evaluate interaction of INAwith viral
RNA.
To test the efficacy of INA-inactivated VEEV to induce
protective antibody response a proof of concept study with INA-
inactivated V3000 was undertaken. Mice were immunized with
INA-inactivatedV3000 as described in Section 2. In the first study, 3
doses of 10,000pfu equivalents of INA-inactivated V3000 induced
a 60% protective response in mice (data not shown). To evalu-
ate if additional immunization and use of adjuvant increase the
protection efficacy we gave an additional immunization dose and
used Alhydrogel and CFA adjuvant in the second study. Alhydro-
gel is an approved adjuvant for human use and has been shown
to increase the protection in gamma irradiated V3526 immunized
mice [41]. CFA is also a potent adjuvant and was used to compare
the response to Alhydrogel and to determine if use of adjuvant
increases the protective efficacy. INA-inactivated V3000 alone still
Table 2
Immunization with INA-inactivated VEEV protected mice from virulent VEEV challenge.
Group(s) Vaccine study (10,000pfu) protection (%)
(total died/total mice)
Vaccine study (50,000pfu) protection (%)
(total died/total mice)
Non-vaccinated 0a (10/10)b 0 (5/5)
Inactivated V3000c 60 (4/10) 78.94 (4/19)
Inactivated V3000+CFA d 80 (2/10) –
Inactivated V3000+Alhydrogele 90 (1/10) –
Micewere vaccinated as described in Section 2. Upon challengewith virulent V3000, non-vaccinatedmice developed clinical symptoms of disease such as ruffled fur, hunched
posture, excitability and hind limb paralysis. All the non-vaccinated mice succumbed to the virulent V3000 challenge. Mean survival time (MST) of non-vaccinated mice in
10,000 and 50,000pfu studies was 10.25 and 8.8 days, respectively. Sixty-percent of mice that were vaccinated with INA-inactivated V3000 alone survived the challenge
with virulent virus. Protection with INA-inactivated V3000 vaccine increased with the use of CFA and Alhydrogel to 80% and 90%, respectively.
a Percent protection.
b Total died/total number.
c V3000 inactivated with 100M dose of INA in combination with irradiation.
d Complete Freund’s adjuvant.
e Aluminum hydroxide containing 2mg/ml of aluminum.
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conferred 60% protection. In, adjuvanted INA-inactivated V3000
groups the protective efficacy increased to 80% and 90% with the
use of CFA and Alhydrogel, respectively (Table 2). Since increas-
ing the number of immunizations did not affect the protective
efficacy of INA-inactivated V3000 alone, we next tested the effect
of increasing the immunization dose of INA-inactivated V3000 to
50,000pfuequivalents. Protectionagainst virulentV3000 increased
to 80% from 60% as was seen with 10,000pfu equivalent dosages.
As expected, all the non-immunized mice succumbed to challenge
with virulent VEEV (Table 2). None of the mice inoculated with the
INA-inactivated V3000 in the above three studies showed any clin-
ical symptoms of disease such as hunched back, anxiety, loss of
appetite and hind limb paralysis. Though further experiments are
needed to establish complete protective dose of INA-inactivated
V3000, these experiments demonstrate the protective efficacy of
INA-inactivated V3000. The serum antibody response was vari-
able in the group vaccinated with INA-inactivated V3000 alone,
some mice had an antibody titer of >log10 2.1 and some mice had
titers <log10 2.0. Use of CFA resulted in a more uniform antibody
response compared to the INA-inactivated V3000 alone group that
was approximately log10 2.1. Use of Alhydrogel resulted in a uni-
formly higher antibody response (p=0.00036) compared to the
INA-inactivated V3000 alone group (Fig. 2). Adjuvants such as CpG
and Alhydrogel have been shown to enhance the antibody titers
and protection in mice immunized with gamma irradiated V3526
[41]. These results are similar to those demonstrated by otherswith
influenza and Ebola viruses where INA-inactivated viruses induced
protective antibody response to respective viruses [32,33].
We also demonstrate in vitro that INA can efficiently inactivate
the live attenuated vaccine strain V3526 of VEEV. Live attenuated
V3526 has shown excellent protective efficacy in animal models
[17,18] and robust immune response in phase I clinical trial
[25]. However, its development as a live attenuated vaccine was
halted due to a flu-like syndrome and fever in the recipients
[24,25]. Therefore, it will be desirable to inactivate V3526 in a
way that conserves its immunogenicity to generate a safer vaccine
candidate without any residual virulence. Since INA inactivates
virulent VEEV strain, V3000 [26] and has been shown to conserve
Fig. 2. Serum antibody titer in mice vaccinated with INA-inactivated V3000. Serum
anti-VEEV antibody titer was evaluated using ELISA as described in Section 2. Vac-
cination with INA-inactivated V3000 alone resulted in variable anti-VEEV antibody
titer within the group. Incorporation of CFA adjuvant in the vaccine resulted in a
more uniform anti-VEEV antibody titer within the group (p=0.021). Use of Alhydro-
gel as an adjuvant in the vaccine resulted in consistently higher anti-VEEV antibody
titer within the group (p=0.00036). Symbols in each group indicate antibody titer
in individual mice.
the virion surface epitopes [31–33] we used INA to inactivate
V3526. A 100M dose of INA completely inactivated the live
V3526. INA-inactivated V3526 did not induce cytopathic effect
(CPE) or cell death in Vero cells (Fig. 3A). Treatment of cells with
free INA showed no toxicity up to 200M dosages ruling out any
cell death due to free INA in the solution (Supplementary Fig. 1).
No virus replication was detected either in the supernatant of
Fig. 3. V3526 inactivation by INA. Vero cells were infected with V3526 or INA-inactivated V3526. (A) Cell death: at 72h p.i., cells infected with V3526 were rounded and
sloughed off the surface. Cells infected with INA-inactivated V3526 grew normally and formed a monolayer similar to that of the saline treated cells. Live cells were stained
bluewith 0.1% CV solution and absence of the blue color indicates loss of cells due to virus infection. (B) Virus titer in the cell supernatant of VERO cells infectedwith V3526 or
INA-inactivated V3526was determined by plaque assay. No viruswas detected in the supernatant of the cells infectedwith INA-inactivated V3526. (C) RT-PCRwas performed
on the RNA isolated from the cells to determine V3526 infection in cells. Cells infected with INA-inactivated V3526 did not show positive amplification of nsp4 gene where
as cells infected with V3526 were positive for nsp4 gene expression (M=marker, 1 =V3526, 2 = INA-inactivated V3526 and, 3 = saline treated cells), and (D) virus titer was
determined in 20% brain tissue homogenate (w/v) of suckling mice that succumbed to the virus infection and the mice that survived the infection. All the mice infected with
INA-inactivated V3526 survived the 13 day p.i. observation period and no virus was detected in the brain, whereas all the mice infected with the V3526 showed positive
virus replication. Each symbol in B and C represent virus titer in individual sample or animal, respectively.
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Fig. 4. Localization of V3526 infection in VERO cells. VERO cells were infected with V3526 or INA-inactivated V3526 with anMOI of 10. Cells were fixed and stained for VEEV
antigen as described in Section 2. VEEV specific antigen (green fluorescence) was localized in the cells infected with V3526 as indicated by arrows. No VEEV specific staining
was observed in the cells infected with INA-inactivated V3526 suggesting failure of INA-inactivated V3526 to replicate in the cells. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
or in the cells infected with INA-inactivated V3526 (Fig. 3B and
C). Immunofluorescence staining for V3526 antigen in the cells
infected with the INA-inactivated V3526 also did not show any
VEEV specific staining (Fig. 4). These results corroborated our pre-
vious findings with V3000 strain of VEEV [26] and also with other
reports of inactivation of influenza, Ebola, HIV and SIV viruses by
INA [31–33]. Further RNA isolated from the INA-inactivated V3526
did not show any infectivity (Supplementary Fig. 2).We also tested
the INA-inactivated V3526 for any residual virulence in suckling
mice. Suckling mice inoculated i.c. with V3526 developed the
disease and either succumbed to the infection within 48–96h p.i.
or were humanely euthanized at 96h p.i. due to disease morbidity
such as stunted growth, slow breathing rate and little to no move-
ment (Table 1). None of the mice which received INA-inactivated
V3526 showed any clinical symptoms of disease such as, hunched
posture, stunted growth, lethargic or paralysis and grew similar to
that of the control mice. Further studies are in progress to evaluate
the protective efficacy of INA-inactivated V3526.
These results have significant implications as INA-inactivated
VEEV overcomes the residual virulence reported with the vaccine
strains forVEEV, i.e. TC-83,V3526withoutpotentially degenerating
the surface antigenic epitopes as seen with formalin inactivation.
INA-inactivation also appears to render the positive sense RNA
genome non-infectious thereby inactivating by two independent
mechanisms of inactivation and thus has an added advantage over
the existing methods of inactivation. VEEV is endemic in the Cen-
tral and South America and has long been considered a potential
biothreat agent. Current IND TC-83 vaccine has limited use due to
20% non responder rate and poor protection from other subtypes
of VEEV. Therefore, there remains an urgent need for an effective
vaccine for immunization against VEEV. These results show that
INA-inactivated VEEV is safe and can protect against virulent VEEV
challenge inmice. Therefore, this strategy of virus inactivationmay
prove beneficial for the production of safe and immunogenic inac-
tivated alphavirus vaccines.
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